Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects aged18 and 50 years inclusive; BMI between 18 and 28 kg/m2 and body weight between 50 and 80 kg.~* Physical examinations and vital signs are normal or abnormal without clinical significance.~* Abdominal color Doppler ultrasound, laboratory tests, etc. are normal or abnormal without clinical significance.~Exclusion Criteria:~* Any current or history of severe allergic reaction to foods or drugs and History of allergy to study products.~* Having severe injuries or surgery or fractures within 4 weeks before enrollment,or to receive surgery during the study.~* Having clinically significantclinical history abnormalities or other clinically indicated diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, mental or cardiovascular diseases).~* Having malignant tumor (excluding basal cell carcinoma who has undergone resection).~* Having clinically significant chronic or acute infections at screening/incorporation; or active infections,Includes acute and chronic infections as well as local infections (bacteria, viruses, parasites, fungi or other opportunities) Sexually infected pathogen).~* Having a history of tuberculosis or latent tuberculosis or clinical manifestations suspected of being tuberculosis(including But not limited to tuberculosis).~* Having been exposed to tuberculosis or/and suspected tuberculosis symptoms and/or signs within 3 months before screening.~* Having used simponi,or any anti-tumor necrosis factor (TNF-α) biologic preparation or any biological products within 6 months before enrollment or monoclonal antibodies within a month.~* Having used drugs within 30 days before enrollment (including but not limited to prescription drugs, Chinese medicine, non-prescription drugs).~* Having vaccinated active / attenuated vaccine within 12 weeks before screening or planned to vaccinate active /attenuated vaccine the during the study.~* Having a history of hypertension or systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ at screening/inclusion90 mmHg, and it is judged abnormalities with clinical significance.~* Electrocardiogram (ECG) examination abnormalities with clinical significance;~* Having positive detection of golimumab anti-drug antibody (ADA) during screening.~* Chest orthotopic examination abnormalities with clinical significance.~* Tuberculosis enzyme-linked immunospot assay (T-SPOT. TB) positive test,~* Having any alcoholic products within 24 hours prior to the use of the study drug.~* A drug abuse test positive or a history of drug abuse over the past five years.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- BAT2506 injection (Type: EXPERIMENTAL): 50mg ；subcutaneous injection
- Sinponi(EU-licensed) (Type: ACTIVE_COMPARATOR): 50mg ；subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete